Art

J-GLOBAL ID：201302294669697064   Reference number：13A0136331

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

転移性腎細胞癌におけるスニチニブとソラフェニブの皮膚毒性と有効性 全国レジストリに基づく研究

Author (9)： POPRACH A. (Masaryk Memorial Cancer Inst. Oncology, Brno, CZE) ,  PAVLIK T. (Masaryk Univ., Brno, CZE) ,  MELICHAR B. (Palacky Univ. Medical School, Olomouc, CZE) ,  PUZANOV I. (Vanderbilt Univ. Medical Center, Nashville, USA) ,  DUSEK L. (Masaryk Univ., Brno, CZE) ,  BORTLICEK Z. (Masaryk Univ., Brno, CZE) ,  VYZULA R. (Masaryk Memorial Cancer Inst. Oncology, Brno, CZE) ,  ABRAHAMOVA J. (Charles Univ., Prague, CZE) ,  BUCHLER T. (Charles Univ., Prague, CZE)
Material： Annals of Oncology  (Ann Oncol)
Volume： 23  Issue： 12  Page： 3137-3143  Publication year： Dec. 2012 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *tyrosine kinase inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A0136331&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Urogenital tumors(=neoplasms)  (GM04000S)

Substance index (2)： Sunitinib ,  Sorafenib

Reference (23)：

• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
• Cunningham D, Hurnblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
• Puzanov I, Michaelson MD, Cohen DP et al. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients ( pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J Clin Oncol 2011; 29(suppl): abstract e21113.
• Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1(2 Suppl): S41-S54.

Terms in the title (7)： 転移性腎細胞癌 ,  スニチニブ ,  ソラフェニブ ,  皮膚毒性 ,  有効性 ,  レジストリ ,  研究